secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jasper Therapeutics, Inc. (JSPR)
CIK:        0001788028
Form:       8-K
Filed at:   2025-05-12T23:59:59+00:00
Accession:  0001213900-25-042017
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jasper Therapeutics Q1 2025 net loss $21.2M; cash $48.8M; briquilimab programs on track
--------------------------------------------------------------------------------

- Net loss of $21.2M ($1.41 per share) for Q1 2025; R&D expenses $16.2M, G&A $5.6M.
- Cash and equivalents totaled $48.8M as of March 31, 2025.
- BEACON CSU study data (including OLE) expected first half of Q3 2025; Phase 2b planned for H2 2025.
- SPOTLIGHT CIndU study full cohort enrolled; additional data at EAACI June 2025.
- ETESIAN asthma allergen challenge study enrolling; initial data expected H2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1788028/000121390025042017/0001213900-25-042017-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1788028/000121390025042017/ea0241732-8k_jasper.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-042017

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer